Tehran University of Medical Sciences

Science Communicator Platform

Stay connected! Follow us on X network (Twitter):
Share this content! On (X network) By
Efficacy of Nivolumab As Checkpoint Inhibitor Drug on Survival Rate of Patients With Relapsed/Refractory Classical Hodgkin Lymphoma: A Meta-Analysis of Prospective Clinical Study Publisher Pubmed



Amraee A1 ; Evazi MR2 ; Shakeri M3 ; Roozbeh N4 ; Ghazanfarpour M5 ; Ghorbani M6 ; Ansari J7 ; Darvish L4, 8
Authors
Show Affiliations
Authors Affiliations
  1. 1. Department of Medical Physics, Faculty of Medicine, School of Medicine, Iran University of Medical Sciences, Tehran, Iran
  2. 2. Hematologist and Medical Oncologist, Hormozgan University of Medical Science, Bandar Abbas, Iran
  3. 3. Department of Radiology and Radiotherapy, Allied Medical Sciences School, Tehran University of Medical Sciences, Tehran, Iran
  4. 4. Mother and Child Welfare Research Center, Hormozgan University of Medical Sciences, Bandar Abbas, Iran
  5. 5. Department of Midwifery, Razi School of Nursing and Midwifery, Kerman University of Medical Sciences, Kerman, Iran
  6. 6. Biomedical Engineering and Medical Physics Department, Faculty of Medicine, Shahid Beheshti University of Medical Sciences, Tehran, Iran
  7. 7. Department of Radiotherapy & Oncology, Arak University of Medical Sciences, Arak, Iran
  8. 8. Department of Radiology, Faculty of Paramedicine, Hormozgan University of Medical Sciences, Bandar Abbas, Iran

Source: Clinical and Translational Oncology Published:2019


Abstract

Aims: The primary standard treatment for classic Hodgkin's lymphoma (cHL) is chemotherapy and radiation therapy. However, some patients get relapsed, or their diseases become resistant. PD1 blocking antibodies have been used to increase the response of treatment in solid tumors, and led to potentially stable responses that are acceptable. Our purpose in this study is to investigate the effect of nivolumab as a PD1 blocking antibody on the survival rate of patients with Hodgkin's cancer. Methods: Databases were found in International Medical Sciences, Web of Science, Medline, Scopus, Index Copernicus, PubMed, DOAJ, Google Scholar, EBSCO-CINAHL, and Persian databases containing SID and Magiran using keywords such as: “checkpoint inhibitor”, “nivolumab”, “Hodgkin lymphoma”, and “PD1 Blockade”. The risk of bias was determined by two external observers using the Cochrane checklists. After the search, the data provided in 51 documents was independently evaluated. Duplicate papers were excluded. Assessing the full texts of the remaining papers, 7 papers were approved. Results: Pooled data of these seven studies revealed that the overall objective response rate was 68% (CI 64.1% to 72.1%; heterogeneity; I2 = 40.19%; p = 0.123) with partial remission (52%; CI 46.5% to 57.6%; heterogeneity; I2 = 28.36%; p = 0.212). In the pooled analysis, complete remission was 16.8 (CI 11.1% to 26.4%). Pooled data of six studies showed that stable disease was averaged to 19% (CI 16% to 23%; heterogeneity; I2 = 30%; p = 0.209; fixed-effect model). Conclusions: The results of the study indicate that nivolumab as a PD1 pathway inhibitor can be effective in treating relapsed and refractory cHL patients compared to other therapies, and lead to more effective treatment over the long term. Furthermore, the adverse effects of nivolumab are controllable and have a good safety profile. © 2019, Federacion de Sociedades Espanolas de Oncologia (FESEO).
Related Docs
View other Related Docs
1. Pd-1 and Cancer: Molecular Mechanisms and Polymorphisms, Immunogenetics (2018)
2. Tumor Immunology, Clinical Immunology (2022)
3. Immunopathology and Immunotherapy of Hodgkin Lymphoma, Cancer Immunology: Cancer Immunotherapy for Organ-Specific Tumors (2020)
4. Immune Checkpoint Inhibition in Classical Hodgkin Lymphoma, Expert Review of Anticancer Therapy (2021)
5. Immune Checkpoints and Ncrnas: Pioneering Immunotherapy Approaches for Hematological Malignancies, Cancer Cell International (2024)
6. Cancer Immunotherapy Confers a Global Benefit, Cancer Immunology: Cancer Immunotherapy for Organ-Specific Tumors (2020)
7. Immunotherapy of Cancers Comes of Age, Expert Review of Clinical Immunology (2017)
8. Immunotherapeutic Approaches in Cancer, Vaccines for Cancer Immunotherapy: An Evidence-Based Review on Current Status and Future Perspectives (2019)
Experts (# of related papers)
View all Related Experts
Nima Rezaei (17)
Hamid Reza Mirzaei (1)
Other Related Docs
9. Targeting the Pd-1/Pd-L1 Pathway in Glioblastoma Multiforme: Preclinical Evidence and Clinical Interventions, International Immunopharmacology (2021)
10. Cancer Immunology, Encyclopedia of Infection and Immunity (2022)
11. Immune Checkpoint Inhibitors Therapy As the Game-Changing Approach for Pediatric Lymphoma: A Brief Landscape, Critical Reviews in Oncology/Hematology (2024)
12. How Micrornas Affect the Pd-L1 and Its Synthetic Pathway in Cancer, International Immunopharmacology (2020)
13. Therapeutic Monoclonal Antibodies for Non-Hodgkin Lymphoma: A Literature Review, Current Cancer Therapy Reviews (2024)
14. Immunotherapeutic Approaches in Cancer, Vaccines for Cancer Immunotherapy: An Evidence-Based Review on Current Status and Future Perspectives (2018)
15. Biomarkers for Predicting the Outcome of Various Cancer Immunotherapies, Critical Reviews in Oncology/Hematology (2021)
16. Pd-1/Pd-L1 Pathway: Basic Biology and Role in Cancer Immunotherapy, Journal of Cellular Physiology (2019)
17. Cancer Imaging With Radiolabeled Monoclonal Antibodies, Cancer Immunology: A Translational Medicine Context# Second Edition (2020)
18. Exhaustion of T Lymphocytes in the Tumor Microenvironment: Significance and Effective Mechanisms, Cellular Immunology (2017)
19. Biomarkers for Immune Checkpoint Inhibitors, Cancer Immunology: Bench to Bedside Immunotherapy of Cancers# Second Edition (2020)
20. Applications of Innovation Technologies for Personalized Cancer Medicine: Stem Cells and Gene-Editing Tools, ACS Pharmacology and Translational Science (2023)
21. The Evolving Landscape of Predictive Biomarkers in Immuno-Oncology With a Focus on Spatial Technologies, Clinical and Translational Immunology (2020)
22. Shedding Light on the Side Effects of Immunotherapies Used for Leukemia: An Updated Review of the Literature, Expert Review of Anticancer Therapy (2023)
23. Recent Advances in Immune Checkpoint Therapy in Non-Small Cell Lung Cancer and Opportunities for Nanoparticle-Based Therapy, European Journal of Pharmacology (2021)
24. Resistance Mechanisms to Programmed Cell Death Protein 1 and Programmed Death Ligand 1 Inhibitors, Expert Opinion on Biological Therapy (2021)
25. Immunopathology and Immunotherapy of Non-Hodgkin Lymphoma, Cancer Immunology: Cancer Immunotherapy for Organ-Specific Tumors (2020)
26. Immune Checkpoint Inhibitors: Review of the Existing Evidence and Challenges in Breast Cancer, Immunotherapy (2021)
27. Cancer Immunotherapy Confers a Global Benefit, Cancer Immunology: Cancer Immunotherapy for Organ-Specific Tumors (2015)
28. Pancancer Analysis Identifies Prognostic High-Apobec1 Expression Level Implicated in Cancer In-Frame Insertions and Deletions, Carcinogenesis (2018)